AAV-M3
AAV-M3 has been studied in 1 paper since 2020: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Nov 30, 2020: “IL-10 based immunomodulation initiated at birth extends lifespan in a familial mouse model of amyotrophic lateral sclerosis”.
1 paper studies it1 findingUpdated
- 1 lab in 1 country
- Funders: National Institute of Neurological Disorders and Stroke and 1 more
- Animals1
What did studies of AAV-M3 find?
1Studies of AAV-M3 measured 1 outcome; the most studied are microglial burden (1 study).
Microglial burden
downin mice1
1 study
Microglial burden
downin mice1
AAV-M3 decreases microglial burden in mice.
“while IL-10 expression increased microglial burden, the IL-10 + M3 group showed lower microglial burden, suggesting that M3 can successfully lower microgliosis before disease onset”
Animalsin presymptomatic SOD1-G93A mice expressing IL-10
Scientific reports